Cargando…
Inhibition of interleukin‐12 and/or interleukin‐23 for the treatment of psoriasis: What is the evidence for an effect on malignancy?
Immune cells and cytokines play an important role in the pathogenesis of psoriasis. Interleukin‐12 (IL‐12) and IL‐23 promote cellular responses mediated by T cells, which contribute to an inflammatory loop responsible for the induction and maintenance of psoriatic plaques. Antibodies that inhibit IL...
Autores principales: | Ergen, Elizabeth N., Yusuf, Nabiha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023723/ https://www.ncbi.nlm.nih.gov/pubmed/29704872 http://dx.doi.org/10.1111/exd.13676 |
Ejemplares similares
-
Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis
por: Koutruba, Nora, et al.
Publicado: (2010) -
2349 The role of interleukin-23 in human melanoma
por: Jani, Aditi, et al.
Publicado: (2018) -
The Interleukin-23/Interleukin-17 Axis Links Adaptive and Innate Immunity in Psoriasis
por: Schön, Michael P., et al.
Publicado: (2018) -
Erythema multiforme after initiation of anti interleukin-12/23 (ustekinumab) treatment for plaque psoriasis
por: Burlando, Martina, et al.
Publicado: (2020) -
Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities
por: Menter, Alan, et al.
Publicado: (2021)